BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 17056201)

  • 1. A prospective phase I-II trial of the cyclooxygenase-2 inhibitor celecoxib in patients with carcinoma of the cervix with biomarker assessment of the tumor microenvironment.
    Herrera FG; Chan P; Doll C; Milosevic M; Oza A; Syed A; Pintilie M; Levin W; Manchul L; Fyles A
    Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):97-103. PubMed ID: 17056201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term performance of interstial fluid pressure and hypoxia as prognostic factors in cervix cancer.
    Fyles A; Milosevic M; Pintilie M; Syed A; Levin W; Manchul L; Hill RP
    Radiother Oncol; 2006 Aug; 80(2):132-7. PubMed ID: 16920212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized double-blind placebo-controlled phase II trial of the cyclooxygenase-2 inhibitor Celecoxib in the treatment of cervical dysplasia.
    Farley JH; Truong V; Goo E; Uyehara C; Belnap C; Larsen WI
    Gynecol Oncol; 2006 Nov; 103(2):425-30. PubMed ID: 16677697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase II study of acute toxicity for Celebrex (celecoxib) and chemoradiation in patients with locally advanced cervical cancer: primary endpoint analysis of RTOG 0128.
    Gaffney DK; Winter K; Dicker AP; Miller B; Eifel PJ; Ryu J; Avizonis V; Fromm M; Greven K
    Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):104-9. PubMed ID: 17084549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Double blind randomized phase II study with radiation+5-fluorouracil+/-celecoxib for resectable rectal cancer.
    Debucquoy A; Roels S; Goethals L; Libbrecht L; Van Cutsem E; Geboes K; Penninckx F; D'Hoore A; McBride WH; Haustermans K
    Radiother Oncol; 2009 Nov; 93(2):273-8. PubMed ID: 19747744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the effectiveness and tolerability of lidocaine patch 5% versus celecoxib for osteoarthritis-related knee pain: post hoc analysis of a 12 week, prospective, randomized, active-controlled, open-label, parallel-group trial in adults.
    Kivitz A; Fairfax M; Sheldon EA; Xiang Q; Jones BA; Gammaitoni AR; Gould EM
    Clin Ther; 2008 Dec; 30(12):2366-77. PubMed ID: 19167595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interstitial fluid pressure predicts survival in patients with cervix cancer independent of clinical prognostic factors and tumor oxygen measurements.
    Milosevic M; Fyles A; Hedley D; Pintilie M; Levin W; Manchul L; Hill R
    Cancer Res; 2001 Sep; 61(17):6400-5. PubMed ID: 11522633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analgesic efficacy of celecoxib in postoperative oral surgery pain: a single-dose, two-center, randomized, double-blind, active- and placebo-controlled study.
    Cheung R; Krishnaswami S; Kowalski K
    Clin Ther; 2007; 29 Suppl():2498-510. PubMed ID: 18164917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Celecoxib decreases prostaglandin E2 concentrations in nipple aspirate fluid from high risk postmenopausal women and women with breast cancer.
    Sauter ER; Qin W; Schlatter L; Hewett JE; Flynn JT
    BMC Cancer; 2006 Oct; 6():248. PubMed ID: 17049084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Celecoxib in the treatment of primary dysmenorrhea: results from two randomized, double-blind, active- and placebo-controlled, crossover studies.
    Daniels S; Robbins J; West CR; Nemeth MA
    Clin Ther; 2009 Jun; 31(6):1192-208. PubMed ID: 19695387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancer.
    Mutter R; Lu B; Carbone DP; Csiki I; Moretti L; Johnson DH; Morrow JD; Sandler AB; Shyr Y; Ye F; Choy H
    Clin Cancer Res; 2009 Mar; 15(6):2158-65. PubMed ID: 19276291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pilot randomized phase II study of celecoxib in oral premalignant lesions.
    Papadimitrakopoulou VA; William WN; Dannenberg AJ; Lippman SM; Lee JJ; Ondrey FG; Peterson DE; Feng L; Atwell A; El-Naggar AK; Nathan CO; Helman JI; Du B; Yueh B; Boyle JO
    Clin Cancer Res; 2008 Apr; 14(7):2095-101. PubMed ID: 18381950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study.
    Sieper J; Klopsch T; Richter M; Kapelle A; Rudwaleit M; Schwank S; Regourd E; May M
    Ann Rheum Dis; 2008 Mar; 67(3):323-9. PubMed ID: 17616556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term improvement in treatment outcome after radiotherapy and hyperthermia in locoregionally advanced cervix cancer: an update of the Dutch Deep Hyperthermia Trial.
    Franckena M; Stalpers LJ; Koper PC; Wiggenraad RG; Hoogenraad WJ; van Dijk JD; Wárlám-Rodenhuis CC; Jobsen JJ; van Rhoon GC; van der Zee J
    Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1176-82. PubMed ID: 17881144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of pharmacokinetic modulating chemotherapy combined with cisplatin as induction chemotherapy in resectable locally advanced head and neck cancer: phase II study.
    Chang PM; Chen PM; Chu PY; Wang LW; Tai SK; Tsai TL; Huang JL; Wang YF; Chang SY; Yang MH
    Cancer Chemother Pharmacol; 2008 Dec; 63(1):9-17. PubMed ID: 18343925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical impact of MRI assisted dose volume adaptation and dose escalation in brachytherapy of locally advanced cervix cancer.
    Pötter R; Dimopoulos J; Georg P; Lang S; Waldhäusl C; Wachter-Gerstner N; Weitmann H; Reinthaller A; Knocke TH; Wachter S; Kirisits C
    Radiother Oncol; 2007 May; 83(2):148-55. PubMed ID: 17531904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular events associated with the use of four nonselective NSAIDs (etodolac, nabumetone, ibuprofen, or naproxen) versus a cyclooxygenase-2 inhibitor (celecoxib): a population-based analysis in Taiwanese adults.
    Huang WF; Hsiao FY; Wen YW; Tsai YW
    Clin Ther; 2006 Nov; 28(11):1827-36. PubMed ID: 17213003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does celecoxib potentiate the anticoagulant effect of warfarin? A randomized, double-blind, controlled trial.
    Dentali F; Douketis JD; Woods K; Thabane L; Foster G; Holbrook A; Crowther M
    Ann Pharmacother; 2006; 40(7-8):1241-7. PubMed ID: 16804099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of the efficacy and safety of celecoxib 200 mg and celecoxib 400 mg once daily in treating the signs and symptoms of psoriatic arthritis.
    Kivitz AJ; Espinoza LR; Sherrer YR; Liu-Dumaw M; West CR
    Semin Arthritis Rheum; 2007 Dec; 37(3):164-73. PubMed ID: 17570469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancement of glioblastoma radioresponse by a selective COX-2 inhibitor celecoxib: inhibition of tumor angiogenesis with extensive tumor necrosis.
    Kang KB; Wang TT; Woon CT; Cheah ES; Moore XL; Zhu C; Wong MC
    Int J Radiat Oncol Biol Phys; 2007 Mar; 67(3):888-96. PubMed ID: 17293239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.